Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
56
ATXS Quote, Financials, Valuation and Earnings
Last price:
$13.01
Seasonality move
:
28.87%
Day range:
$12.86 - $13.04
52-week range:
$3.56 - $13.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,061.67x
P/B ratio:
5.38x
Volume:
660.3K
Avg. volume:
1.3M
1-year change:
36.06%
Market cap:
$742.7M
Revenue:
--
EPS (TTM):
-$2.15
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ATXS
Astria Therapeutics, Inc.
|
$10.7M | -$0.42 | -- | -1.3% | $24.60 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$974.1M | $1.75 | 98.51% | -58.59% | $491.92 |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$163M | $0.07 | 14.24% | -83.33% | $20.60 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
HOLX
Hologic, Inc.
|
$1B | $1.10 | 5.06% | 26.35% | $76.50 |
|
JNJ
Johnson & Johnson
|
$23.8B | $2.76 | 7.18% | 79.14% | $209.29 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ATXS
Astria Therapeutics, Inc.
|
$13.01 | $24.60 | $742.7M | -- | $0.00 | 0% | 1,061.67x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$400.79 | $491.92 | $52.9B | 1,666.49x | $0.00 | 0% | 16.44x |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$7.70 | $20.60 | $1.6B | -- | $0.00 | 0% | 2.77x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
HOLX
Hologic, Inc.
|
$74.50 | $76.50 | $16.6B | 30.00x | $0.00 | 0% | 4.13x |
|
JNJ
Johnson & Johnson
|
$207.78 | $209.29 | $500.6B | 20.05x | $1.30 | 2.47% | 5.47x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ATXS
Astria Therapeutics, Inc.
|
1.88% | 2.900 | 0.88% | 10.42x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
92.22% | 1.279 | 4.61% | 2.37x |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
231.39% | 0.424 | 42.75% | 1.60x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
HOLX
Hologic, Inc.
|
34.23% | 1.299 | 17.49% | 2.91x |
|
JNJ
Johnson & Johnson
|
36.62% | 0.235 | 10.26% | 0.71x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ATXS
Astria Therapeutics, Inc.
|
-- | -$34.1M | -42.21% | -42.95% | -4830.6% | -$32.3M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1B | $368M | 1.51% | 31.15% | 29.46% | $313M |
|
BCRX
BioCryst Pharmaceuticals, Inc.
|
$156.9M | $29.6M | -2.54% | -- | 18.57% | $39.8M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
HOLX
Hologic, Inc.
|
$580.7M | $253M | 7.59% | 11.59% | 24.11% | $324.7M |
|
JNJ
Johnson & Johnson
|
$16.7B | $7.1B | 20.94% | 33.27% | 29.64% | $8B |
Astria Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ATXS or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of 20.1%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 31.15%.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics, Inc.-- -$0.55 $237.7M ALNYAlnylam Pharmaceuticals, Inc.83.98% $1.84 $3B -
What do Analysts Say About ATXS or ALNY?
Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 90.7%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 23.38%. Given that Astria Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Astria Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics, Inc.1 7 0 ALNYAlnylam Pharmaceuticals, Inc.14 7 0 -
Is ATXS or ALNY More Risky?
Astria Therapeutics, Inc. has a beta of 0.076, which suggesting that the stock is 92.449% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.301, suggesting its less volatile than the S&P 500 by 69.879%.
-
Which is a Better Dividend Stock ATXS or ALNY?
Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or ALNY?
Astria Therapeutics, Inc. quarterly revenues are $706K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.2B. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $251.1M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 1,666.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,061.67x versus 16.44x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics, Inc.1,061.67x -- $706K -$31.6M ALNYAlnylam Pharmaceuticals, Inc.16.44x 1,666.49x $1.2B $251.1M
-
Which has Higher Returns ATXS or BCRX?
BioCryst Pharmaceuticals, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of 8.09%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat BioCryst Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics, Inc.-- -$0.55 $237.7M BCRXBioCryst Pharmaceuticals, Inc.98.42% $0.06 $295.2M -
What do Analysts Say About ATXS or BCRX?
Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 90.7%. On the other hand BioCryst Pharmaceuticals, Inc. has an analysts' consensus of $20.60 which suggests that it could grow by 173.57%. Given that BioCryst Pharmaceuticals, Inc. has higher upside potential than Astria Therapeutics, Inc., analysts believe BioCryst Pharmaceuticals, Inc. is more attractive than Astria Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics, Inc.1 7 0 BCRXBioCryst Pharmaceuticals, Inc.6 1 0 -
Is ATXS or BCRX More Risky?
Astria Therapeutics, Inc. has a beta of 0.076, which suggesting that the stock is 92.449% less volatile than S&P 500. In comparison BioCryst Pharmaceuticals, Inc. has a beta of 0.909, suggesting its less volatile than the S&P 500 by 9.061%.
-
Which is a Better Dividend Stock ATXS or BCRX?
Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioCryst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. BioCryst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or BCRX?
Astria Therapeutics, Inc. quarterly revenues are $706K, which are smaller than BioCryst Pharmaceuticals, Inc. quarterly revenues of $159.4M. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than BioCryst Pharmaceuticals, Inc.'s net income of $12.9M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while BioCryst Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,061.67x versus 2.77x for BioCryst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics, Inc.1,061.67x -- $706K -$31.6M BCRXBioCryst Pharmaceuticals, Inc.2.77x -- $159.4M $12.9M
-
Which has Higher Returns ATXS or CRMD?
CorMedix, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of 49.9%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics, Inc.-- -$0.55 $237.7M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ATXS or CRMD?
Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 90.7%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that Astria Therapeutics, Inc. has higher upside potential than CorMedix, Inc., analysts believe Astria Therapeutics, Inc. is more attractive than CorMedix, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics, Inc.1 7 0 CRMDCorMedix, Inc.4 0 0 -
Is ATXS or CRMD More Risky?
Astria Therapeutics, Inc. has a beta of 0.076, which suggesting that the stock is 92.449% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock ATXS or CRMD?
Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or CRMD?
Astria Therapeutics, Inc. quarterly revenues are $706K, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,061.67x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics, Inc.1,061.67x -- $706K -$31.6M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns ATXS or HOLX?
Hologic, Inc. has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of 17.85%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat Hologic, Inc.'s return on equity of 11.59%.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics, Inc.-- -$0.55 $237.7M HOLXHologic, Inc.55.33% $0.83 $7.7B -
What do Analysts Say About ATXS or HOLX?
Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 90.7%. On the other hand Hologic, Inc. has an analysts' consensus of $76.50 which suggests that it could grow by 2.69%. Given that Astria Therapeutics, Inc. has higher upside potential than Hologic, Inc., analysts believe Astria Therapeutics, Inc. is more attractive than Hologic, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics, Inc.1 7 0 HOLXHologic, Inc.3 15 0 -
Is ATXS or HOLX More Risky?
Astria Therapeutics, Inc. has a beta of 0.076, which suggesting that the stock is 92.449% less volatile than S&P 500. In comparison Hologic, Inc. has a beta of 0.703, suggesting its less volatile than the S&P 500 by 29.745%.
-
Which is a Better Dividend Stock ATXS or HOLX?
Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. Hologic, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ATXS or HOLX?
Astria Therapeutics, Inc. quarterly revenues are $706K, which are smaller than Hologic, Inc. quarterly revenues of $1B. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than Hologic, Inc.'s net income of $187.3M. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while Hologic, Inc.'s PE ratio is 30.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,061.67x versus 4.13x for Hologic, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics, Inc.1,061.67x -- $706K -$31.6M HOLXHologic, Inc.4.13x 30.00x $1B $187.3M
-
Which has Higher Returns ATXS or JNJ?
Johnson & Johnson has a net margin of -4482.01% compared to Astria Therapeutics, Inc.'s net margin of 21.47%. Astria Therapeutics, Inc.'s return on equity of -42.95% beat Johnson & Johnson's return on equity of 33.27%.
Company Gross Margin Earnings Per Share Invested Capital ATXSAstria Therapeutics, Inc.-- -$0.55 $237.7M JNJJohnson & Johnson69.72% $2.12 $125.1B -
What do Analysts Say About ATXS or JNJ?
Astria Therapeutics, Inc. has a consensus price target of $24.60, signalling upside risk potential of 90.7%. On the other hand Johnson & Johnson has an analysts' consensus of $209.29 which suggests that it could grow by 0.73%. Given that Astria Therapeutics, Inc. has higher upside potential than Johnson & Johnson, analysts believe Astria Therapeutics, Inc. is more attractive than Johnson & Johnson.
Company Buy Ratings Hold Ratings Sell Ratings ATXSAstria Therapeutics, Inc.1 7 0 JNJJohnson & Johnson9 11 0 -
Is ATXS or JNJ More Risky?
Astria Therapeutics, Inc. has a beta of 0.076, which suggesting that the stock is 92.449% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.
-
Which is a Better Dividend Stock ATXS or JNJ?
Astria Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.47% to investors and pays a quarterly dividend of $1.30 per share. Astria Therapeutics, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ATXS or JNJ?
Astria Therapeutics, Inc. quarterly revenues are $706K, which are smaller than Johnson & Johnson quarterly revenues of $24B. Astria Therapeutics, Inc.'s net income of -$31.6M is lower than Johnson & Johnson's net income of $5.2B. Notably, Astria Therapeutics, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 20.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astria Therapeutics, Inc. is 1,061.67x versus 5.47x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ATXSAstria Therapeutics, Inc.1,061.67x -- $706K -$31.6M JNJJohnson & Johnson5.47x 20.05x $24B $5.2B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
